CJC-1295 (No DAC) + Ipamorelin

Description

CJC-1295 (No DAC) + Ipamorelin is a two-compound research blend combining CJC-1295 without Drug Affinity Complex (10 mg) and Ipamorelin (10 mg) in a single lyophilized vial. CJC-1295 No DAC, also known as Modified GRF (1–29), is a tetra-substituted analog of GHRH(1–29) in which four amino acids are replaced to resist enzymatic cleavage while retaining the short-acting profile of the native fragment. Ipamorelin is a selective pentapeptide agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Together they represent the most widely studied GHRH-analog + GHRP pairing in the literature, acting on complementary receptors within the same somatotroph signaling axis. It is supplied here for controlled analytical and laboratory investigation of dual-pathway growth hormone secretagogue signaling.

Research focus

• Combined GHRH-receptor and GHS-R1a (ghrelin receptor) activation
• Short-acting, pulse-preserving growth hormone release models
• Comparison with the DAC-conjugated form and with longer-acting analogs such as Tesamorelin

This Medtruva catalog product is a laboratory research material, not a clinical product. Store and prepare it only according to an appropriate research protocol, and review all available documentation before use.

For laboratory research use only. Not for human consumption, diagnosis, treatment, or veterinary use.